COMMUNIQUÉ DE PRESSE publié le 13/01/2025 à 08:17, il y a 1 année 7 mois Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma Heidelberg Pharma advances into Cohort 7 with BCMA ATAC candidate HDP-101 targeting multiple myeloma, showing promising results and complete remission in Phase I/IIa study Heidelberg Pharma Multiple Myeloma Phase I/IIa Study Complete Remission BCMA ATAC
BRÈVE publiée le 06/11/2024 à 10:07, il y a 1 année 9 mois Heidelberg Pharma Reveals Promising Data on HDP-101 at ASH 2024 Clinical Data Heidelberg Pharma HDP-101 ADC Technology Multiple Myeloma
BRÈVE publiée le 06/11/2024 à 10:07, il y a 1 année 9 mois Heidelberg Pharma dévoile des données prometteuses sur le HDP-101 à l'ASH 2024 Heidelberg Pharma HDP-101 Myélome Multiple Données Cliniques Technologie ADC
COMMUNIQUÉ DE PRESSE publié le 06/11/2024 à 10:02, il y a 1 année 9 mois Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024 Heidelberg Pharma AG to present promising new clinical data on lead ADC-candidate HDP-101 at ASH Annual Meeting 2024, showcasing potential for multiple myeloma treatment Clinical Data HDP-101 Heidelberg Pharma AG ADC ASH Annual Meeting
BRÈVE publiée le 24/10/2024 à 11:08, il y a 1 année 10 mois Heidelberg Pharma to Showcase Its ADC Innovations in November 2024 Cancer Therapy Heidelberg Pharma HDP-101 ADCs HDP-201
BRÈVE publiée le 24/10/2024 à 11:08, il y a 1 année 10 mois Heidelberg Pharma présentera ses innovations ADC en novembre 2024 Heidelberg Pharma HDP-101 Thérapie Contre Le Cancer ADC HDP-201
COMMUNIQUÉ DE PRESSE publié le 24/10/2024 à 11:03, il y a 1 année 10 mois Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024 Heidelberg Pharma to present ADC candidates at scientific and financial conferences in November 2024. Updates on Amanitin-based HDP-101 and Exatecan-based HDP-201. Key targets and conference details Heidelberg Pharma Scientific Conferences ADC Candidates Amanitin Exatecan
BRÈVE publiée le 10/10/2024 à 07:11, il y a 1 année 10 mois Heidelberg Pharma AG's Interim Report for First Nine Months of 2024 Financial Report Heidelberg Pharma HDP-101 Trial Clinical Outcomes Royalty Sale
BRÈVE publiée le 10/10/2024 à 07:11, il y a 1 année 10 mois Rapport intermédiaire de Heidelberg Pharma AG pour les neuf premiers mois de 2024 Rapport Financier Heidelberg Pharma Résultats Cliniques Essai Du HDP-101 Vente De Redevances
COMMUNIQUÉ DE PRESSE publié le 10/10/2024 à 07:06, il y a 1 année 10 mois Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024 Heidelberg Pharma AG provides insights on its operational progress and financial figures for the first nine months of fiscal year 2024. Development activities, new clinical data, R&D webinars, and guidance updates are highlighted Financial Figures Clinical Data Heidelberg Pharma AG R&D Webinars Guidance Updates
Publié le 28/08/2026 à 14:00, il y a 7 heures 51 minutes Lobe Sciences Expands Leadership Team with New CFO Appointment
Publié le 28/08/2026 à 13:00, il y a 8 heures 51 minutes Abasca Files NI 43-101 Technical Report, Commences Summer Exploration Program at Loki and Elects to File Semi-annual Interim Financial Statements and Related MD&A
Publié le 28/08/2026 à 08:05, il y a 13 heures 46 minutes Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
Publié le 28/08/2026 à 08:05, il y a 13 heures 46 minutes Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
Publié le 28/08/2026 à 08:00, il y a 13 heures 51 minutes Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate
Publié le 28/08/2026 à 20:49, il y a 1 heure 1 minute Publication pursuant to Article 5(1)(b) and (3) of Regulation (EU) No. 596/2014 and Article 2(2) and (3) of the Commission Delegated Regulation (EU) No. 2016/1052 - Final Announcement
Publié le 28/08/2026 à 20:42, il y a 1 heure 9 minutes Aroundtown SA: Release of a capital market information
Publié le 28/08/2026 à 19:10, il y a 2 heures 40 minutes Invitation to Professional or Qualified Investors holding Notes to submit offers for Branicks Bridge Notes and VIB Bridge Notes
Publié le 28/08/2026 à 18:01, il y a 3 heures 49 minutes CPI Europe announces unaudited results for the first half of 2026
Publié le 28/08/2026 à 18:00, il y a 3 heures 51 minutes Highlight Event and Entertainment AG publishes results for the first half of 2026